Developer docs
API playgroundTry for free, no card

Search company profiles

Gliknik

Full company profile

uuid0002biu

Namestring
Gliknik
Legal namestring
Gliknik Inc.
Websiteurl
gliknik.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Gliknik is a privately held, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Baltimore, Maryland. The company develops recombinant biologics designed to modulate the immune system for patients with autoimmune diseases and cancer. Its core technology is a proprietary platform of multivalent Fc fusion proteins ("stradomers") that mimic or extend the activity of pooled human immunoglobulin (IVIg). The lead clinical assets are GL-2045, a recombinant IVIg mimetic currently in a Phase 2 trial in Immune Thrombocytopenia (ITP), and GL-0719, a recombinant Fc fusion protein that selectively inhibits the classical and lectin complement pathways, currently in a Phase 2 trial in Cold Agglutinin Disease (NCT05318534). Both candidates have reported favorable safety profiles with no drug-related serious adverse events across approximately 95 combined study participants.

Gliknik's business model is asset-light and partnership-driven rather than commercial: the company licenses or divests drug rights to large pharmaceutical partners who fund and execute late-stage development, regulatory, and commercialization activities. The defining commercial relationship is with Pfizer, which licensed GL-2045 in September 2013 (renamed PF-06755347), triggered a $15M milestone payment in February 2019 upon clinical progress, and purchased additional autoimmune drug rights for $25 million in October 2024. The company has raised approximately $16.4 million across disclosed Series B ($4.9M, Baxter Ventures, October 2012) and Series C ($11.5M, June 2021) financings, and holds 13 issued U.S. patents across 5 patent families protecting its stradomer platform.

Gliknik operates with a lean team of 1-10 employees focused on drug discovery and early-stage clinical development in Baltimore. Revenue, where recognized, comes from upfront payments, development milestones, and potential royalties on partnered assets rather than product sales, leaving the company effectively pre-revenue on a recurring basis. The leadership team and board include former big-pharma operators and biotech founders (notably former Incyte CEO Paul A. Friedman and Pharmasset founder Raymond F. Schinazi), reinforcing Gliknik's positioning as a science-led, partnership-validated clinical-stage biotech rather than a vertically integrated commercial organization.

Short descriptiontext

Gliknik is a clinical-stage biopharmaceutical company developing recombinant biologic drug candidates, including GL-2045 and GL-0719, for patients with autoimmune and complement-mediated diseases. The company monetizes its stradomer platform primarily through licensing partnerships, notably with Pfizer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, recombinant biologics, autoimmune disease therapies, Fc fusion proteins, complement pathway modulators
Industry4 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Gliknik generates revenue through licensing agreements with pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical progress, and royalties on commercialized products. Notable example: $15 million milestone payment from Pfizer for clinical progress with GL-2045 (PF-06755347).

gliknik.com
2Drug Rights Acquisitions
TypeLicensing Royalties
Description

Sale of drug rights and assets to pharmaceutical companies. Example: Pfizer bought autoimmune disease drug rights from Gliknik for $25 million.

gliknik.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1GL-2045
Description

A recombinant version of the active fraction of IVIg, designed as a substitute for the blood product IVIg for treating autoimmune diseases such as Immune Thrombocytopenia (ITP).

gliknik.com
+2 more records
Core offering1 text field

Gliknik discovers and develops recombinant biologic drug candidates for autoimmune diseases and immune disorders. Its lead clinical assets are GL-2045, a recombinant IVIg mimetic (stradomer) in Phase 2 for Immune Thrombocytopenia, and GL-0719, a recombinant Fc fusion protein in Phase 2 for Cold Agglutinin Disease. The company monetizes these assets through licensing, milestone, and royalty agreements with large pharmaceutical partners, most notably Pfizer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • GL-2045 has been generally safe and well tolerated with no drug-related Serious Adverse Events in approximately 45 study participants who have received GL-2045 SC.
+2 more records
Product overview1 text field

Gliknik is a privately held biopharmaceutical company developing innovative biologics for immune disorders. The company's clinical-stage portfolio includes GL-2045, a recombinant IVIg mimetic for autoimmune diseases like ITP, and GL-0719, a complement pathway modulator for complement-mediated diseases including Cold Agglutinin Disease. Both drug candidates are designed as recombinant alternatives to plasma-derived products, offering advantages in potency, convenience (subcutaneous injection), supply consistency, and safety. The company also advanced GL-0817 (a cancer immunomodulator) and has licensed GL-2045 (PF-06755347) to Pfizer.

Product and service2 records
1GL-2045
CategoryDrug candidate (clinical-stage biologic)
Description

Recombinant version of the active fraction of intravenous immunoglobulin (IVIg), designed as a multimerized Fc protein (stradomer) for subcutaneous administration in autoimmune diseases including Immune Thrombocytopenia (ITP) and CIDP. Licensed to Pfizer as PF-06755347.

2GL-0719
CategoryDrug candidate (clinical-stage biologic)
Description

Recombinant Fc fusion protein designed to selectively inhibit the classical and lectin complement pathways upstream in the complement cascade for treating complement-mediated autoimmune diseases, with Cold Agglutinin Disease as the lead indication.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2013-09-30
Description

Gliknik entered into a licensing agreement with Pfizer for a drug candidate targeting autoimmune diseases. Pfizer acquired rights to GL-2045 (renamed PF-06755347) and related compounds. The partnership includes milestone payments and royalties. Pfizer received orphan drug designation from FDA for the drug candidate directed towards a rare neurological disorder. Pfizer subsequently paid $15 million milestone payment for clinical progress and $25 million for additional autoimmune disease drug rights.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Gliknik has been represented by Cooley LLP on intellectual property matters for approximately a decade, handling patent filings worldwide.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Argenx develops Fc-based biologics (efgartigimod/Vyvgart) for autoimmune diseases including ITP. The most direct comparability to Gliknik: same Fc receptor biology, same ITP indication overlap, and similar strategy of replacing IVIg mechanisms with engineered recombinant antibodies.

TypeDirect peer
Description

Apellis developed pegcetacoplan (Empaveli/Aspaveli) for complement-mediated diseases including Cold Agglutinin Disease, directly overlapping with Gliknik's GL-0719 development program. Comparable clinical-stage complement therapeutics company with similar indication focus.

TypeBroad incumbent
Description

Alexion commercializes eculizumab (Soliris) and ravulizumab (Ultomiris), the established C5 complement inhibitors. Direct mechanistic overlap with Gliknik's GL-0719 in complement-mediated diseases, with broad rare disease portfolio and significantly greater resources.

4Viela Bio
TypeDirect peer
Description

Viela Bio was a clinical-stage autoimmune biologics company (anti-CD19/inebilizumab) acquired by Horizon Therapeutics. Direct peer to Gliknik as a small autoimmune-focused biotech; both targeted B-cell and complement-mediated diseases with biologic modalities.

TypeDirect peer
Description

Momenta was a clinical-stage autoimmune biologics company (targeting Fc receptor pathways) acquired by Johnson & Johnson. Highly comparable to Gliknik in therapeutic focus on autoimmune disease and Fc receptor modulation, with a similar small-biotech development model.

TypeDirect peer
Description

Ra Pharma developed peptide complement inhibitors (zilucoplan) and was acquired by UCB. Direct peer in complement therapeutics with similar clinical-stage development profile and strategic exit pathway via big-pharma acquisition.

TypeBroad incumbent
Description

BioMarin is an established rare-disease biopharmaceutical company with a biologic modality focus. Comparable to Gliknik in targeting small, underserved autoimmune and rare disease populations with biologics, and as a potential acquirer profile for clinical-stage assets.

TypeEmerging player
Description

Kiniksa is a clinical-stage immunology-focused biotech (rilonacept, mavrilimumab) with board overlap to Gliknik via Richard S. Levy. Comparable as a small-cap immunology biotech pursuing niche autoimmune indications with biologics.

TypeEmerging player
Description

AnaptysBio is a clinical-stage antibody platform company developing therapeutics for inflammatory and autoimmune diseases. Comparable to Gliknik in the protein-engineering platform approach and autoimmune therapeutic area focus.

TypeOthers
Description

Madrigal is led by Paul A. Friedman (also a Gliknik board member) and successfully developed resmetirom for NASH. Relevant as a comparable small-biotech commercial trajectory under shared board leadership, though in a different therapeutic area.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gliknik

Clinical-stage Biopharmaceuticalsgliknik.com

Gliknik is a clinical-stage biopharmaceutical company developing recombinant biologic drug candidates, including GL-2045 and GL-0719, for patients with autoimmune and complement-mediated diseases. The company monetizes its stradomer platform primarily through licensing partnerships, notably with Pfizer.

What Gliknik does

Gliknik is a privately held, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Baltimore, Maryland. The company develops recombinant biologics designed to modulate the immune system for patients with autoimmune diseases and cancer. Its core technology is a proprietary platform of multivalent Fc fusion proteins ("stradomers") that mimic or extend the activity of pooled human immunoglobulin (IVIg). The lead clinical assets are GL-2045, a recombinant IVIg mimetic currently in a Phase 2 trial in Immune Thrombocytopenia (ITP), and GL-0719, a recombinant Fc fusion protein that selectively inhibits the classical and lectin complement pathways, currently in a Phase 2 trial in Cold Agglutinin Disease (NCT05318534). Both candidates have reported favorable safety profiles with no drug-related serious adverse events across approximately 95 combined study participants.

Gliknik's business model is asset-light and partnership-driven rather than commercial: the company licenses or divests drug rights to large pharmaceutical partners who fund and execute late-stage development, regulatory, and commercialization activities. The defining commercial relationship is with Pfizer, which licensed GL-2045 in September 2013 (renamed PF-06755347), triggered a $15M milestone payment in February 2019 upon clinical progress, and purchased additional autoimmune drug rights for $25 million in October 2024. The company has raised approximately $16.4 million across disclosed Series B ($4.9M, Baxter Ventures, October 2012) and Series C ($11.5M, June 2021) financings, and holds 13 issued U.S. patents across 5 patent families protecting its stradomer platform.

Gliknik operates with a lean team of 1-10 employees focused on drug discovery and early-stage clinical development in Baltimore. Revenue, where recognized, comes from upfront payments, development milestones, and potential royalties on partnered assets rather than product sales, leaving the company effectively pre-revenue on a recurring basis. The leadership team and board include former big-pharma operators and biotech founders (notably former Incyte CEO Paul A. Friedman and Pharmasset founder Raymond F. Schinazi), reinforcing Gliknik's positioning as a science-led, partnership-validated clinical-stage biotech rather than a vertically integrated commercial organization.

Gliknik firmographics

Firmographics
Name
Gliknik
Legal name
Gliknik Inc.
Website
https://gliknik.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Gliknik is a clinical-stage biopharmaceutical company developing recombinant biologic drug candidates, including GL-2045 and GL-0719, for patients with autoimmune and complement-mediated diseases. The company monetizes its stradomer platform primarily through licensing partnerships, notably with Pfizer.
Ownership category
akta.pro rank

Gliknik industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biopharmaceutical
  • Recombinant biologics
  • Autoimmune disease therapies
  • Fc fusion proteins
  • Complement pathway modulators

Where Gliknik is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Gliknik business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Gliknik generates revenue through licensing agreements with pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical progress, and royalties on commercialized products. Notable example: $15 million milestone payment from Pfizer for clinical progress with GL-2045 (PF-06755347).
  2. Drug Rights Acquisitions: Sale of drug rights and assets to pharmaceutical companies. Example: Pfizer bought autoimmune disease drug rights from Gliknik for $25 million.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Gliknik product offering

Product offering

Core offering

Gliknik discovers and develops recombinant biologic drug candidates for autoimmune diseases and immune disorders. Its lead clinical assets are GL-2045, a recombinant IVIg mimetic (stradomer) in Phase 2 for Immune Thrombocytopenia, and GL-0719, a recombinant Fc fusion protein in Phase 2 for Cold Agglutinin Disease. The company monetizes these assets through licensing, milestone, and royalty agreements with large pharmaceutical partners, most notably Pfizer.

Product overview

Gliknik is a privately held biopharmaceutical company developing innovative biologics for immune disorders. The company's clinical-stage portfolio includes GL-2045, a recombinant IVIg mimetic for autoimmune diseases like ITP, and GL-0719, a complement pathway modulator for complement-mediated diseases including Cold Agglutinin Disease. Both drug candidates are designed as recombinant alternatives to plasma-derived products, offering advantages in potency, convenience (subcutaneous injection), supply consistency, and safety. The company also advanced GL-0817 (a cancer immunomodulator) and has licensed GL-2045 (PF-06755347) to Pfizer.

Differentiator

Problem solved

Functional benefit

Brands

  • GL-2045: A recombinant version of the active fraction of IVIg, designed as a substitute for the blood product IVIg for treating autoimmune diseases such as Immune Thrombocytopenia (ITP).
  • GL-0719
  • Stradomers

Products and services

  • GL-2045 Recombinant version of the active fraction of intravenous immunoglobulin (IVIg), designed as a multimerized Fc protein (stradomer) for subcutaneous administration in autoimmune diseases including Immune Thrombocytopenia (ITP) and CIDP. Licensed to Pfizer as PF-06755347.
  • GL-0719 Recombinant Fc fusion protein designed to selectively inhibit the classical and lectin complement pathways upstream in the complement cascade for treating complement-mediated autoimmune diseases, with Cold Agglutinin Disease as the lead indication.

Quantifiable outcome

  • GL-2045 has been generally safe and well tolerated with no drug-related Serious Adverse Events in approximately 45 study participants who have received GL-2045 SC.
  • +2 more outcomes

Companies that use Gliknik

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Gliknik technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gliknik partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Pfizer Inc.flagshipOEM/ Whitelabel/ Licensing Partner · 30 September 2013Gliknik entered into a licensing agreement with Pfizer for a drug candidate targeting autoimmune diseases. Pfizer acquired rights to GL-2045 (renamed PF-06755347) and related compounds. The partnership includes milestone payments and royalties. Pfizer received orphan drug designation from FDA for the drug candidate directed towards a rare neurological disorder. Pfizer subsequently paid $15 million milestone payment for clinical progress and $25 million for additional autoimmune disease drug rights.
  • Cooley LLPcoreImplementation/ SI/ Consulting PartnerGliknik has been represented by Cooley LLP on intellectual property matters for approximately a decade, handling patent filings worldwide.

Scale indicators6 records

Recent moves2 records

Expansion highlights6 records

Gliknik competitors and assessment

Company assessment

Direct peers

  • argenx: Argenx develops Fc-based biologics (efgartigimod/Vyvgart) for autoimmune diseases including ITP. The most direct comparability to Gliknik: same Fc receptor biology, same ITP indication overlap, and similar strategy of replacing IVIg mechanisms with engineered recombinant antibodies.
  • Apellis Pharmaceuticals: Apellis developed pegcetacoplan (Empaveli/Aspaveli) for complement-mediated diseases including Cold Agglutinin Disease, directly overlapping with Gliknik's GL-0719 development program. Comparable clinical-stage complement therapeutics company with similar indication focus.
  • Viela Bio: Viela Bio was a clinical-stage autoimmune biologics company (anti-CD19/inebilizumab) acquired by Horizon Therapeutics. Direct peer to Gliknik as a small autoimmune-focused biotech; both targeted B-cell and complement-mediated diseases with biologic modalities.
  • Momenta Pharmaceuticals: Momenta was a clinical-stage autoimmune biologics company (targeting Fc receptor pathways) acquired by Johnson & Johnson. Highly comparable to Gliknik in therapeutic focus on autoimmune disease and Fc receptor modulation, with a similar small-biotech development model.
  • Ra Pharmaceuticals: Ra Pharma developed peptide complement inhibitors (zilucoplan) and was acquired by UCB. Direct peer in complement therapeutics with similar clinical-stage development profile and strategic exit pathway via big-pharma acquisition.

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Alexion commercializes eculizumab (Soliris) and ravulizumab (Ultomiris), the established C5 complement inhibitors. Direct mechanistic overlap with Gliknik's GL-0719 in complement-mediated diseases, with broad rare disease portfolio and significantly greater resources.
  • BioMarin Pharmaceutical: BioMarin is an established rare-disease biopharmaceutical company with a biologic modality focus. Comparable to Gliknik in targeting small, underserved autoimmune and rare disease populations with biologics, and as a potential acquirer profile for clinical-stage assets.

Emerging players

  • Kiniksa Pharmaceuticals: Kiniksa is a clinical-stage immunology-focused biotech (rilonacept, mavrilimumab) with board overlap to Gliknik via Richard S. Levy. Comparable as a small-cap immunology biotech pursuing niche autoimmune indications with biologics.
  • AnaptysBio: AnaptysBio is a clinical-stage antibody platform company developing therapeutics for inflammatory and autoimmune diseases. Comparable to Gliknik in the protein-engineering platform approach and autoimmune therapeutic area focus.

Others

  • Madrigal Pharmaceuticals: Madrigal is led by Paul A. Friedman (also a Gliknik board member) and successfully developed resmetirom for NASH. Relevant as a comparable small-biotech commercial trajectory under shared board leadership, though in a different therapeutic area.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Gliknik social profiles

Digital presence

Gliknik financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gliknik leadership team

Management profile

Number of profiles

Profiles9 records

Gliknik funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gliknik M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gliknik

What does Gliknik do?

Gliknik discovers and develops recombinant biologic drug candidates for autoimmune diseases and immune disorders. Its lead clinical assets are GL-2045, a recombinant IVIg mimetic (stradomer) in Phase 2 for Immune Thrombocytopenia, and GL-0719, a recombinant Fc fusion protein in Phase 2 for Cold Agglutinin Disease. The company monetizes these assets through licensing, milestone, and royalty agreements with large pharmaceutical partners, most notably Pfizer.

Is Gliknik a public or private company?

Gliknik is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gliknik founded?

Gliknik was founded in 2007. It employs 1 to 10 people.

Where is Gliknik based?

Gliknik is headquartered in Baltimore, United States, in the North America region.

How does Gliknik make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are drug Rights Acquisitions.

Who are Gliknik's main competitors?

Direct peers on record are argenx, Apellis Pharmaceuticals, Viela Bio, Momenta Pharmaceuticals and Ra Pharmaceuticals. Broad incumbents are Alexion (AstraZeneca Rare Disease) and BioMarin Pharmaceutical. Emerging players are Kiniksa Pharmaceuticals and AnaptysBio. Madrigal Pharmaceuticals is listed as an others.

Does Gliknik have an API?

No public API is recorded for Gliknik.

What industry is Gliknik in?

Gliknik's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PatsnapDrug pipelines, Patents, Clinical trialsPfizer has discontinued the development of two orphan drug candidates, recifercept and PF-06755347, as part of a strategic review of its rare disease research and development pipeline. PF-06755347 was a recombinant Fc fusion protein developed in collaboration with Gliknik, Inc., which received $15 million for the program's entry into Phase 1 trials four years ago.University of MarylandInvesting in Innovation at UMBUM Ventures, Baltimore's equity investment program has invested just under $2 million in 12 UMB startups since 2014, with four acquired. The portfolio has raised $95 million in follow-on funding, and recent investments include Gliknik, Sonosa, and Protaryx, signaling a rebound in biotech investment.American City Business JournalsBaltimore's Gliknik raising $16M to combat autoimmune drug shortageGliknik raised $5.3 million of a planned $16 million funding round to fund phase one clinical trials for two autoimmune drugs, GL-2045 and GL-0719. The drugs aim to replace IVIG and complement modulators with home-injection therapies, addressing a worldwide IVIG shortage. Phase two trials are planned for 2024.GoogleFUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONSThe invention discloses fusion proteins combining human IgG Fc domains with multimerization domains to create orderly multimerized immunoglobulin Fc compositions. These biomimetics aim to address shortcomings of intravenous immunoglobulin (IVIG), such as high protein load, infectious risk, and IgA anaphylaxis, while maintaining therapeutic efficacy. The molecules are intended for treating autoimmune and inflammatory disorders.FinSMEsGliknik Raises $11.5M in Series C FinancingGliknik Inc. completed an $11.5 million Series C financing round led by First In Ventures, with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. The company intends to use the funds to advance its pipeline of biologic drug candidates for cancer and autoimmune disorders. This brings Gliknik's total funding to $81 million as it prepares for upcoming clinical trials.Business Wire BlogGliknik Inc. Raises $11.5 Million in Series C FinancingGliknik Inc. completed an $11.5 million Series C financing led by First In Ventures, with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. The company has raised $81 million to date, and the funds will advance its pipeline, including a phase 2 study of biropepimut-S and a phase 1 trial of GL-0719 in 2021.Venture Capital Access OnlineGliknik Inc. Raises $11.5 Million in Series C FinancingGliknik Inc. completed an $11.5 million Series C financing led by First In Ventures, with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. The company has raised $81 million to date to advance its pipeline, including a phase 2 study of biropepimut-S and a phase 1 trial for GL-0719 in 2021.PR NewswireGliknik Announces Dosing Of First Patient In Phase 2 Trial Targeting Prevention Of Recurrence Of High-Risk Oral Cavity CancerGliknik Inc. announced that clinicians have enrolled and dosed the first patient in a Phase 2 clinical trial evaluating biropepimut-S (GL-0817), an immunomodulatory therapeutic designed to prevent recurrence of squamous cell cancer of the oral cavity in patients at high risk despite prior surgery, chemotherapy, and radiation. The randomized, double-blind, placebo-controlled trial will enroll 80 patients at 45 sites across the U.S., Germany, Hungary, Poland, Serbia, Spain, and Ukraine, with participants receiving 10 vaccinations over a two-year period. Biropepimut-S has received Orphan Drug designation from the U.S. FDA for MAGE-A3 expressing head and neck squamous cell cancer.WsjGliknik Licenses Autoimmune-Diseases Drug Rights to PfizerGliknik Inc. licensed its autoimmune-diseases drug GL-2045 to Pfizer for $25 million up front plus milestone payments. The drug is designed to replace pooled human intravenous immunoglobulin, and Gliknik reported promising preclinical results.PfizerGliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune DiseasesGliknik Inc. announced an exclusive worldwide licensing agreement with Pfizer for GL-2045, a recombinant stradomer drug candidate designed to replace pooled human intravenous immunoglobulin in autoimmune diseases. Gliknik will receive a $25 million upfront payment plus development, regulatory, commercial milestones and tiered double-digit royalties. GL-2045 is in IND-enabling manufacturing.